Document Detail

Biomarkers and cytokines of bone turnover: extensive evaluation in a cohort of patients with ankylosing spondylitis.
Jump to Full Text
MedLine Citation:
PMID:  23025387     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Ankylosing spondylitis (AS) is a chronic inflammatory disease of spine and sacroiliac joints; it is characterized by new bone formation, and the disease processes can be accompanied by osteoporosis. In the present study, we investigated changes in bone mineral density (BMD) and in the levels of various bone turnover-related biomarkers and cytokines in a cohort of AS patients, with regard to clinical parameters, disease activity, and treatment regimen.
METHODS: 55 AS patients and 33 healthy controls included in the study. Spinal mobility was assessed by the Bath Ankylosing Spondylitis Metrology Index (BASMI), and radiologic changes were scored by the Bath Ankylosing Spondylitis Radiologic Index (BASRI). Patients were also evaluated with the Bath Ankylosing Spondylitis Functional Index (BASFI) and the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI). Bone mineral density (BMD) assessed by dual energy X-ray absorptiometry. Various biomarkers and cytokines of bone turnover including osteoprotegerin (OPG), serum band 5 tartrate-resistant acid phosphatase (TRAP-5), soluble receptor activator of nuclear factor kappa-B ligand (sRANKL), secreted frizzled-related protein 1 (sFRP-1), Dickkopf-related protein 1 (DKK-1), and sclerostin were studied.
RESULTS: The levels of TRAP-5, NTX, sRANKL, sclerostin, sFRP-1, DKK-1, and IFNγ, were similar between the patients and controls (p > 0.05), while BMD of femoral neck, and OPG levels were significantly lower in AS patients (p < 0.05). In a subgroup analysis, patients with active disease had significantly higher concentrations of OPG compared with the inactive group. Rest of the biomarkers and cytokines of bone turnover were similar between the active and inactive disease groups. Subgroup analysis of patients receiving anti-TNFα agents and conventional therapy revealed that OPG concentrations were significantly lower in the patients receiving biological drugs, while BAP and DKK-1 were significantly higher in the patients treated with conventional agents.
CONCLUSIONS: In this cross-sectional study we showed that OPG levels were significantly lower in AS patients compared to healthy subjects. On the other hand, the levels of wingless (Wnt) signal pathway inhibitors seem not altered. Ectopic bone formation in AS may be related to dysfunction of these molecules at the cellular level.
Authors:
Ali Taylan; Ismail Sari; Baris Akinci; Safak Bilge; Didem Kozaci; Servet Akar; Ayfer Colak; Hulya Yalcin; Necati Gunay; Nurullah Akkoc
Related Documents :
24309407 - Prevalence, clinical characteristics and outcome of pulmonary hypertension among admitt...
23273657 - Pentraxin 3 in the assessment of ventilator-associated pneumonia: an early marker of s...
24096347 - Dengue fever mimicking acute appendicitis: a case report.
23241067 - The value of c-reactive protein in symptomatic versus asymptomatic carotid artery steno...
18775017 - The role of nonacid reflux in nerd: lessons learned from impedance-ph monitoring in 150...
6374867 - Gut hormones in inflammatory bowel disease.
Publication Detail:
Type:  Journal Article     Date:  2012-10-02
Journal Detail:
Title:  BMC musculoskeletal disorders     Volume:  13     ISSN:  1471-2474     ISO Abbreviation:  BMC Musculoskelet Disord     Publication Date:  2012  
Date Detail:
Created Date:  2012-11-08     Completed Date:  2013-03-12     Revised Date:  2013-07-11    
Medline Journal Info:
Nlm Unique ID:  100968565     Medline TA:  BMC Musculoskelet Disord     Country:  England    
Other Details:
Languages:  eng     Pagination:  191     Citation Subset:  IM    
Affiliation:
Izmir Tepecik Training and Research Hospital, Department of Rheumatology, Izmir, Turkey. taylanally@yahoo.com
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Absorptiometry, Photon
Acid Phosphatase / blood
Adult
Biological Markers / blood
Biomechanics
Bone Density
Bone Morphogenetic Proteins / blood
Bone Remodeling*
Case-Control Studies
Cell Cycle Proteins / blood
Cross-Sectional Studies
Cytokines / blood*
Female
Femur Neck / radiography
Genetic Markers
Humans
Immunosuppressive Agents / therapeutic use
Intercellular Signaling Peptides and Proteins / blood
Isoenzymes / blood
Male
Middle Aged
Osteoprotegerin / blood
Protein-Serine-Threonine Kinases / blood
RANK Ligand / blood
Severity of Illness Index
Spine / drug effects,  physiopathology*,  radiography
Spondylitis, Ankylosing / blood,  diagnosis,  drug therapy,  immunology,  physiopathology*
Treatment Outcome
Tumor Necrosis Factor-alpha / antagonists & inhibitors
Young Adult
Chemical
Reg. No./Substance:
0/Biological Markers; 0/Bone Morphogenetic Proteins; 0/Cell Cycle Proteins; 0/Cytokines; 0/DKK1 protein, human; 0/Genetic Markers; 0/Immunosuppressive Agents; 0/Intercellular Signaling Peptides and Proteins; 0/Isoenzymes; 0/Osteoprotegerin; 0/RANK Ligand; 0/SOST protein, human; 0/TNFRSF11B protein, human; 0/TNFSF11 protein, human; 0/Tumor Necrosis Factor-alpha; EC 2.7.1.-/ATR protein, human; EC 2.7.11.1/Protein-Serine-Threonine Kinases; EC 3.1.3.-/tartrate-resistant acid phosphatase; EC 3.1.3.2/Acid Phosphatase
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Full Text
Journal Information
Journal ID (nlm-ta): BMC Musculoskelet Disord
Journal ID (iso-abbrev): BMC Musculoskelet Disord
ISSN: 1471-2474
Publisher: BioMed Central
Article Information
Download PDF
Copyright ©2012 Taylan et al.; licensee BioMed Central Ltd.
open-access:
Received Day: 17 Month: 2 Year: 2012
Accepted Day: 26 Month: 9 Year: 2012
collection publication date: Year: 2012
Electronic publication date: Day: 2 Month: 10 Year: 2012
Volume: 13First Page: 191 Last Page: 191
PubMed Id: 23025387
ID: 3492209
Publisher Id: 1471-2474-13-191
DOI: 10.1186/1471-2474-13-191

Biomarkers and cytokines of bone turnover: extensive evaluation in a cohort of patients with ankylosing spondylitis
Ali Taylan1 Email: taylanally@yahoo.com
Ismail Sari2 Email: ismailsari35@gmail.com
Baris Akinci3 Email: barisakincimd@gmail.com
Safak Bilge4 Email: bilge_1967@hotmail.com
Didem Kozaci5 Email: ldkozaci@yahoo.com
Servet Akar2 Email: servet.akar@gmail.com
Ayfer Colak6 Email: ayfercolak@gmail.com
Hulya Yalcin6 Email: hzafer44@hotmail.com
Necati Gunay7 Email: gunayn@gmail.com
Nurullah Akkoc2 Email: nurullah.akkoc@deu.edu.tr
1Izmir Tepecik Training and Research Hospital, Department of Rheumatology, Izmir, Turkey
2Dokuz Eylul University School of Medicine, Department of Internal Medicine, Division of Rheumatology, Izmir, Turkey
3Izmir Tepecik Training and Research Hospital, Department of Endocrinology, Izmir, Turkey
4Izmir Tepecik Training and Research Hospital, Department of Physical medicine and Rehabilitation, Izmir, Turkey
5Adnan Menderes University School of Medicine, Department of Biochemistry, Aydin, Turkey
6Izmir Tepecik Training and Research Hospital, Department of Biochemistry, Izmir, Turkey
7Adnan Menderes University, Bilim ve Teknoloji Araştirma ve Uygulama Merkezi (ADU-BILTEM), Aydin, Turkey

Background

Ankylosing spondylitis (AS), a chronic inflammatory disease of the spine and sacroiliac joints, is characterized by new bone formation and is thereby associated with syndesmophytes and ankylosis [1]. Osteoporosis is also present in AS and has multiple etiologies [2,3]. Several biomarkers are known to be related to bone turnover. In general, activation of osteoclasts (OCs) plays an important role in bone loss and the development of erosions. Human receptor activator of nuclear factor-κβ ligand (RANKL), a member of the tumor necrosis factor super family, is one molecule that stimulates OCs. In contrast, inhibition of OCs and activation of osteoblasts (OBs) are linked with new bone formation and ossification. Osteoprotegerin (OPG), which is produced by OBs, inhibits RANKL and plays an important role in bone formation [4]. Recently, various components of the Wnt pathway signaling cascade were found to be involved in maintaining bone mass. The most-studied secreted Wnt inhibitors are sclerostin, dickkopfs (Dkks), and secreted frizzled related proteins (sFRP1), which likely play important roles in bone turnover [5].

Various studies have aimed to identify and clarify the mechanisms of bone turnover in AS, which results in new bone formation and, paradoxically, osteoporosis [6-13]. The use of anti-TNF treatments has provided new insights into the treatment of inflammatory rheumatic diseases, particularly AS and rheumatoid arthritis (RA). Current data suggested that formation of syndesmophytes is not prevented by anti-TNF treatments, despite significant clinical improvement [14]. It is not known why bone formation continues even when inflammation is suppressed [14,15]; therefore; further studies are needed to identify pathophysiological mechanisms responsible for new bone formation and osteoporosis in AS. In the current study, we evaluated the biomarkers and cytokines related to bone turnover in AS patients who were treated with conventional agents and anti-TNFs. We also investigated the relationship of bone mineral density with various biomarkers of bone turnover and clinical parameters.


Methods

Fifty-five consecutive patients diagnosed with AS according to modified New York criteria [16], and 33 age- and sex-matched healthy controls were enrolled in this study. Subjects with a history of neuroendocrine disorder (thyroid, parathyroid disorder, and anticonvulsant usage), chronic renal and liver disease, systemic steroid usage, menopause, cigarette smoking, or excessive alcohol usage were excluded from the study.

Patients provided informed written consent to participate, and the study protocol was approved by the ethical committee of the Tepecik Hospital. Spinal mobility was assessed by the Bath Ankylosing Spondylitis Metrology Index (BASMI) [17]. Radiologic changes were scored by the Bath Ankylosing Spondylitis Radiologic Index (BASRI) [18]. Patients were also evaluated with the Bath Ankylosing Spondylitis Functional Index (BASFI) [19] and the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) [20]. Patients with a BASDAI ≥ 4 were defined as having active disease. Conventional treatment included non-steroidal anti-inflammatory drugs (NSAIDs) and/or sulfasalazine, but not anti-TNF-α drugs.

Laboratory evaluation

Following an overnight fast, venous blood samples for laboratory tests were collected between 8:00 and 9:00 AM. Serum samples were preserved at 80°C until assayed. The following ELISA kits were used according to the manufacturer’s instructions: Serum high sensitive C- reactive protein (hs-CRP, Cat. No.: EIA-3954, DRG International, USA), interleukin 6 (IL-6, Cat. No.: EK0410, Boster Biological Technology Co., Ltd., China), vitamin D (Cat. No.: K 2110 ko, ImmunDiagnostik, Bensheim, Germany), bone-specific alkaline phosphatase (BAP, QUIDEL, San Diego, CA, USA), cross-linked N-telopeptide of type I collagen (NTx, Osteomark® NTx serum, Princeton, NJ, USA), serum band 5 tartrate-resistant acid phosphatase (TRAP-5, Cat. No.: RD197025000, Biovendor Laboratory Medicine, Brno, Czech Republic), soluble receptor activator of nuclear factor kappa-B ligand (sRANKL, Cat. No.: RD193004200R, Biovendor Laboratory Medicine, Brno, Czech Republic), osteoprotegerin (OPG, Cat. No.: EK0480, Boster Biological Technology Co., Ltd., China), sclerostin (Cat. No.: BI-20492, Biomedica Gruppe, Vienna, Austria), Dickkopf-related protein 1 (DKK-1, Cat. No.: BI-20412, Biomedica Gruppe, Vienna, Austria), secreted frizzled-related protein 1 (sFRP-1, Cat. No.: E95880Hu, USCN, Wuhan, China), human parathyroid hormone (hPTH, Cat. No.: KAP1481, The DIAsource hPTH-EASIA, Niveles, Belgium) serum interferon-gamma (IFN-γ, Cat. No.: EI1023-1, AssayPro, St. Charles, MO, USA).

Bone densitometry assessment

Axial and appendicular BMD of lumbar spine (L2-L4, posteroanterior view) and the left proximal femur (neck, intertrochanteric area, greater trochanter, and ward’s triangle) were assessed using the AP dual-energy x-ray absorptiometry DEXA (Hologic QDR 1000, Waltham, MA, USA). The results were expressed as g/cm2.

Statistical analysis

The Kolmogorov-Smirnov normality test was used to determine the distribution pattern of the variables. The majority of the parameters including ESR, BAP, DKK-1, hPTH, IL-6, sFRP1, IFN-γ, and sRANKL/OPG ratio showed non-normal distribution, and we used non-parametric tests for the statistical analysis. The Mann–Whitney U-test was used for comparisons between two groups of continuous variables. Fisher's exact test was performed for the comparison of categorical variables. The Spearman’s rho correlation was used to determine relationships between parameters. Results were presented as median with minimum–maximum (range) values. Statistical analysis was carried out using the Statistical Package for the Social Science, version 13.0 (Chicago, IL, USA). A two-tailed p value of <0.05 was considered significant.


Results

Of the 55 AS patients, 48 were male, 7 were female, and the median age was 36 years (range, 19–61); of the 33 healthy controls, 24 were male, 9 were female, and the median age was 39 years (range, 23–48). In the patient group, the median disease duration was 10 (2–40) years. BASDAI, BASFI, BASMI, BASRI hip, and BASRI spine indices were 5 (1–9), 3.7 (0.1–8.8), 3 (1–9), 0 (0–4), and 6 (2–12), respectively. HLAB-27 positivity was 64.9%. None of the individuals had any personal or family history of psoriasis or inflammatory bowel disease. Only one patient had a history of hip prosthesis.

Age and sex distributions were similar between patients and controls (p = non-significant [NS]). Anthropometrical parameters, including body mass index (BMI) and waist circumference, were also comparable between the groups (p = NS). Biochemical examination showed that serum levels of calcium, phosphor, BAP, and vitamin D did not differ between patients and controls (p = NS). However, acute phase proteins, including ESR, hs-CRP, and IL-6, were significantly higher in the AS group (p < 0.05). Bone turnover parameters, including TRAP 5, NTX, sRANKL, sclerostin, sFRP-1, DKK-1, and IFNγ, were similar between the groups (p = NS). On the other hand, hPTH and OPG levels were significantly lower in the AS group [p < 0.05; 46 (44–170) vs. 78 (45–180) pg/mL and 339 (52–1118) vs. 527 (16–1030) pg/mL, respectively]. BMD of femoral neck in the patient group was significantly lower than in the controls [p < 0.05; 0.8 (0.5–1) vs. 0.9 (0.6–1.1) g/cm2]. However, BMD lumbar spine did not differ between the groups (p = NS). The clinical and laboratory characteristics of AS patients and controls are given in Table 1.

Comparison of AS subjects receiving anti-TNF agents and conventional therapy

Thirty-two patients were treated with conventional drugs (NSAIDS and/or sulfasalazine), and 23 were treated with anti-TNFα drugs (9 infliximab, 8 etanercept, and 6 adalimumab). Age distribution was similar between the groups (p = NS). The median treatment duration of biologics was 24 (16–33) months. All subjects treated with TNFα-targeting agents received their treatments regularly, and none of the patients treated with conventional drugs had received anti-TNFα agents in their past medical history. Comparison of the patients on anti-TNFα and conventional drug therapies revealed that all biochemical parameters were similar in both treatment groups (p = NS), except for BAP, DKK-1, and OPG. BAP and DKK-1 concentrations were significantly higher in the patients receiving anti-TNFα drugs [p < 0.05; 33 (17–107) vs. 28 (13–47) U/L, and 108 (39–771) vs. 87 (17–370), pg/mL respectively], while OPG levels were lower [p < 0.05; 274 (52–1080) vs. 384 (84–1118) pg/mL respectively] in the anti-TNFα treatment group compared to conventional therapy. BASRI-hip and -spine indices and BMD assessments (lumbar and femoral neck) did not differ between the treatment groups (p = NS). Table 2 summarizes the parameters of the two treatment groups.

Comparison of AS subjects with respect to disease activity

Thirty-eight AS patients had active disease (BASDAI ≥ 4), and 17 cases were inactive. Age and sex distributions were similar between patients with active and inactive disease (p = NS). Studied bone turnover markers, except OPG, were comparable between active and inactive disease states (p = NS). OPG concentrations were significantly higher in the active AS group compared to the inactive patients [p < 0.05; 367 (52–1118) vs. 274 (71–592) pg/mL). BASRI-hip and -spine indices and BMD assessments (lumbar and femoral neck) were also not different between active and inactive patients (p = NS). Data from patients with active and inactive diseases are shown in Table 3.

Correlation analysis

Upon correlation analysis, sclerostin was found to be correlated with disease duration, lumbar BMD, DKK-1, and PTH (p < 0.05; r = 0.3, 0.2, 0.2, and 0.3, respectively). DKK-1 showed correlations with BASMI, sclerostin, and SFRP-1 (p < 0.05; r = 0.3, 0.2, and −0.2, respectively). sRANKL was correlated with disease duration, BASRI-spine, and BASMI (p < 0.05; r = −0.3, −0.4, and −0.4 respectively). Lumbar BMD was correlated with disease duration, BASRI-spine, femoral neck BMD, BASMI, and sclerostin (p < 0.05; r = 0.3, 0.3, 0.3, 0.4, and 0.2 respectively). OPG showed correlations with BASDAI ≥ 4 (p < 0.05; r = 0.3). Other significant correlations were summarized in Table 4.


Discussion

The present study showed that AS patients had lower serum OPG levels and a higher RANKL/OPG ratio compared to healthy controls. Previous studies have shown discrepancies in regards to OPG level in AS. Some studies revealed elevated OPG levels in AS patients compared to healthy controls [6,9,12]. However, a study in a Korean cohort found no differences in serum levels of OPG between AS patients and normal subjects [11]. In a cohort of 240 AS patients, Franck et al. found that AS patients generally had lower serum OPG level and higher RANKL/OPG ratio; they also reported a lack of compensatory increase of OPG with age in AS patients [8]. Subgroup analysis of our results also revealed that active disease state (BASDAI ≥ 4) was associated with higher OPG levels. This result is in agreement with the findings of Chen et al., who found OPG to be correlated with poor physical mobility and increased inflammatory state in AS patients; however, in contrast to our results, that study found RANKL and OPG to be elevated compared to controls [6]. Osteoprotegerin inhibits osteoclastogenesis by binding RANKL, acting as a decoy receptor to competitively inhibit RANKL interaction with its receptor RANK. Thus, decreased OPG levels in AS patients might have contributed to the lowered BMD detected at femur in our study group [4]. On the other hand, hypothetically, the excess production of OPG during active disease state could contribute to the new bone formation. In this study, we also showed that, anti-TNF treated AS patients had significantly lower levels of OPG compared with the conventionally treated patients. This observation is in line with a prospective study performed by Kwon et al. who showed anti-TNF treatment had a negative effect on OPG concentrations [12].

The discrepancies between the results of various studies may be due to the effects of various disease states and treatment types on the RANKL/OPG axis, as well as the complex interaction of various cytokines and signaling molecules. In our study, RANKL was similar in AS patients and healthy controls, was not altered with treatment, and showed no relation with clinical parameters; in contrast, Kim et al. found increased RANKL level correlating with disease activity markers [11]. RANKL is an important cytokine, but osteoclastogenesis is also influenced by TNF, IL-1, IL-6, IL-17, vitamin D3, and prostaglandin E2 [21,22]. OPG balances bone resorption, and is induced by IL-4, IFNγ, PTH, BMP, and Wnt signaling [23]; all of these cytokines are expressed differently in cases of certain disease activity and treatment. Woo et al. reported that etanercept therapy didn’t change RANKL/OPG levels, but improved bone metabolic markers and BMD in AS patients [24]. In our study, we observed that sRANKL/OPG ratio was significantly higher in patients treated with anti-TNF therapies. Although sRANKL did not change between the treatments groups, this significance was a consequence of lower OPG concentrations in the biological treatment group. The effects of inflammation on bone remodeling have different outcomes in different rheumatic diseases, such as RA and AS [25]. In both diseases, decreased bone mineral density is expected, including juxta-articular osteopenia in RA and decreased BMD mainly at vertebras and hip in AS [2,3]. In this study, BMD of femoral neck was significantly decreased in AS patients, but BMD of lumbar spine did not differ from the healthy controls. These observations may be due to be the interference of syndesmophytes and ectopic calcifications with BMD measurement at lumbar spine. Low PTH and OPG in AS patients may be explanatory to the finding of decreased BMD of femoral neck as we noted previously.

In our study, the serum levels of Wnt signaling pathway inhibitors, DKK-1, Sclerostin, and sFRP1, were not different in AS patients from the healthy controls. However, subgroup analysis showed that patients receiving anti-TNFα treatment had higher DKK-1 levels compared to patients taking conventional drugs. Daoussis et al. recently measured DKK-1 level using two different serum assays; a sandwich Elisa assay that showed circulating DKK-1 indicated that serum DKK-1 was increased in AS patients compared to healthy controls, but a functional ELISA model showed decreased binding of DKK-1 to the LRP-6 receptor [7]. Diarra et al. also found that, in contrast to RA, DKK-1 levels in AS were very low and showed no relation with measures of disease activity [26]. Lane et al. found that higher DKK-1 levels were protective and diminished the risk of radiologic progression for hip OA, another disease associated with bone formation [27]. All of these studies suggest that either dysfunction or decreased level of DKK-1 is crucial for new bone formation in AS. In our study, increased DKK-1 level in AS patients who were on anti-TNF treatment are noteworthy, since the balance between DKK-1 and Wnt is important for bone turnover. In Diarra et al.’s study, DKK-1 levels in RA patients were diminished with anti-TNF drugs, but the effects in AS patients were not clear [26]. According to our results, decreased OPG and increased DKK-1 in patients on anti-TNF therapy suggest a trend favoring osteoclastogenesis in these patients. However, prospective studies are needed to determine the net effect of biological therapies on bone metabolism.


Conclusions

In this cross-sectional study we showed that OPG levels were significantly down regulated in AS patients compared to healthy subjects. Serum concentrations of OPG tend to be higher in patients with active disease state suggesting a trend favoring osteoblastic activity in these patients. The levels of Wnt signal pathway inhibitors seem not altered in AS. Ongoing ectopic bone formation, one of the one of the hallmark features of AS, may be related to dysfunction of these molecules at the cellular level.


Competing interests

The authors declare that they have no competing interests.


Authors’ contributions

DK, AC, HY and NG are carried out all the laboratory analysis in the study. SA read x-rays for BASRI calculation. SB helped to collect data from patients. IS did statical analysis of the results and contributed to discussion, also involved intellectually in project design. NA helped to general design of the paper and supported us, as a head of rheumatology department. BA involved in project design intellectually. AT involved in project design and collected the patient’s data and wrote the paper. All authors read and approved the final manuscript.


Pre-publication history

The pre-publication history for this paper can be accessed here:

http://www.biomedcentral.com/1471-2474/13/191/prepub


Acknowledgements

All the Elisa kits used in the study was provided by Tepecik Teaching and Research Hospital. We did not get support from any company to complete the study. We thank SF edit who provided medical editing services.


References
Schett G,Bone formation versus bone resorption in ankylosing spondylitisAdv Exp Med BiolYear: 200964911412110.1007/978-1-4419-0298-6_819731624
Carter S,Lories RJ,Osteoporosis: a paradox in ankylosing spondylitisCurr Osteoporos RepYear: 2011911211510.1007/s11914-011-0058-z21647573
Magrey M,Khan MA,Osteoporosis in ankylosing spondylitisCurr Rheumatol RepYear: 20101233233610.1007/s11926-010-0122-120680529
Schett G,Joint remodelling in inflammatory diseaseAnn Rheum DisYear: 200766Suppl 3iii42iii4417934094
Schett G,Zwerina J,David JP,The role of Wnt proteins in arthritisNat Clin Pract RheumatolYear: 2008447348010.1038/ncprheum088118756273
Chen CH,Chen HA,Liao HT,Liu CH,Tsai CY,Chou CT,Soluble receptor activator of nuclear factor-kappaB ligand (RANKL) and osteoprotegerin in ankylosing spondylitis: OPG is associated with poor physical mobility and reflects systemic inflammationClin RheumatolYear: 2010291155116110.1007/s10067-010-1543-y20690034
Daoussis D,Liossis SN,Solomou EE,Tsanaktsi A,Bounia K,Karampetsou M,Yiannopoulos G,Andonpoulos AP,Evidence that Dkk-1 is dysfunctional in ankylosing spondylitisArthritis RheumYear: 20106215015810.1002/art.2723120039407
Franck H,Meurer T,Hofbauer LC,Evaluation of bone mineral density, hormones, biochemical markers of bone metabolism, and osteoprotegerin serum levels in patients with ankylosing spondylitisJ RheumatolYear: 2004312236224115517638
Grisar J,Bernecker PM,Aringer M,Redlich K,Sedlak M,Wolozcszuk W,Spitzauer S,Grampp S,Kainberger F,Ebner W,Smolen JS,Pietschmann P,Ankylosing spondylitis, psoriatic arthritis, and reactive arthritis show increased bone resorption, but differ with regard to bone formationJ RheumatolYear: 2002291430143612136902
Im CH,Kang EH,Ki JY,Shin DW,Choi HJ,Chang EJ,Lee EY,Lee YJ,Lee EB,Kim HH,Song YW,Receptor activator of nuclear factor kappa B ligand-mediated osteoclastogenesis is elevated in ankylosing spondylitisClin Exp RheumatolYear: 20092762062519772794
Kim HR,Lee SH,Kim HY,Elevated serum levels of soluble receptor activator of nuclear factors-kappaB ligand (sRANKL) and reduced bone mineral density in patients with ankylosing spondylitis (AS)RheumatologyYear: 2006451197120010.1093/rheumatology/kel07216567356
Kwon SR,Lim MJ,Suh CH,Park SG,Hong YS,Yoon BY,Kim HA,Choi HJ,Park W,Dickkopf-1 level is lower in patients with ankylosing spondylitis than in healthy people and is not influenced by anti-tumor necrosis factor therapyRheumatol IntYear: 20123282523252710.1007/s00296-011-1981-021833531
Uderhardt S,Diarra D,Katzenbeisser J,David JP,Zwerina J,Richards W,Kronke G,Schett G,Blockade of Dickkopf (DKK)-1 induces fusion of sacroiliac jointsAnn Rheum DisYear: 20106959259710.1136/ard.2008.10204619304568
Schett G,Coates LC,Ash ZR,Finzel S,Conaghan PG,Structural damage in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: traditional views, novel insights gained from TNF blockade, and concepts for the futureArthritis Res TherYear: 201113Suppl 1S421624183
Schett G,Structural bone changes in spondyloarthritis: mechanisms, clinical impact and therapeutic considerationsAm J Med SciYear: 2011341426927110.1097/MAJ.0b013e31820f8b2921358309
van der Linden S,Valkenburg HA,Cats A,Evaluation of diagnostic criteria for ankylosing spondylitis. a proposal for modification of the New York criteriaArthritis RheumYear: 19842736136810.1002/art.17802704016231933
Jenkinson TR,Mallorie PA,Whitelock HC,Kennedy LG,Garrett SL,Calin A,Defining spinal mobility in ankylosing spondylitis (AS). The Bath AS Metrology IndexJ RheumatolYear: 199421169416987799351
MacKay K,Mack C,Brophy S,Calin A,The Bath Ankylosing Spondylitis Radiology Index (BASRI): a new, validated approach to disease assessmentArthritis RheumYear: 1998412263227010.1002/1529-0131(199812)41:12<2263::AID-ART23>3.0.CO;2-I9870884
Calin A,Garrett S,Whitelock H,Kennedy LG,O'Hea J,Mallori P,Jenkinson T,A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional IndexJ RheumatolYear: 199421228122857699629
Garrett S,Jenkinson T,Kennedy LG,Whitelock H,Gaisford P,Calin A,A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity IndexJ RheumatolYear: 199421228622917699630
Kotake S,Udagawa N,Takahashi N,Matsuzaki K,Itoh K,Ishiyama S,Saito S,Inoue K,Kamatani N,Gillespie MT,Martin TJ,Suda T,IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesisJ Clin InvestYear: 19991031345135210.1172/JCI570310225978
Take I,Kobayashi Y,Yamamoto Y,Tsuboi H,Ochi T,Uematsu S,Okafuji N,Kurihara S,Udagawa N,Takahashi N,Prostaglandin E2 strongly inhibits human osteoclast formationEndocrinologyYear: 20051465204521410.1210/en.2005-045116150915
Walsh NC,Gravallese EM,Bone remodeling in rheumatic disease: a question of balanceImmunol RevYear: 201023330131210.1111/j.0105-2896.2009.00857.x20193007
Woo JH,Lee HJ,Sung IH,Kim TH,Changes of clinical response and bone biochemical markers in patients with ankylosing spondylitis taking etanerceptJ RheumatolYear: 2007341753175917610317
Schett G,Osteoimmunology in rheumatic diseasesArthritis Res TherYear: 20091121010.1186/ar257119232069
Diarra D,Stolina M,Polzer K,Zwerina J,Ominsky MS,Dwyer D,Korb A,Smolen J,Hoffmann M,Scheinecker C,van der Heide D,Landewe R,Lacey D,Richards WG,Schett G,Dickkopf-1 is a master regulator of joint remodelingNat MedYear: 20071315616310.1038/nm153817237793
Lane EN,Nevitt MC,Lui LY,de Leon P,Corr M,Wnt signaling antagonists are potential prognostic biomarkers for the progression of radiographic hip osteoarthritis in elderly Caucasian womenArthritis RheumYear: 2007563319332510.1002/art.2286717907185

Tables
[TableWrap ID: T1] Table 1 

Clinical and laboratory characteristics of AS patients and controls


  AS Patients (n =55) Controls (n = 33) pvalue
Age (years)
36 (19–61)
39 (23–48)
0.9
Sex (M/F)
48/7
24/9
0.1
BMI (kg/m2)
25 (18–37)
25 (20–31)
0.9
Waist circumference (cm)
92 (66–120)
89 (65–104)
0.2
BMD-Lumbar spine (g/cm2)
0.9 (0.7–1.6)
1 (0.8–1.2)
0.1
BMD-Femoral neck (g/cm2)
0.8 (0.5–1.1)
0.9 (0.6–1.1)
0.002
ESR (mm/h)
17 (3–72)
9 (1–30)
<0.0001
hs-CRP (mg/L)
8.5 (0.6–24.3)
2.5 (0–9.9)
<0.0001
IL-6 (pg/mL)
18.5 (5–545)
8.1 (4–69)
<0.0001
IFNγ (pg/mL)
0.002 (0.002–1.956)
0.002 (0.002–0.313)
0.5
BAP (U/L)
29 (13–107)
26 (2–51)
0.1
Calcium (mg/L)
10 (9–11)
9.9 (9.3–11)
0.7
Phosphor (mg/dL)
1.3 (1.7–4.7)
3.4 (2.2–4,5)
0.9
Vitamin D (nM)
87 (4–266)
102 (10–303)
0.5
NTX (nM, bone collagenequivalent)
82 (52–188)
84 (57–106)
0.3
TRAP 5 (U/L)
3.8 (2.3–6.6)
3.7 (2.3–8.34)
0.3
hPTH (pg/mL)
46 (44–170)
78 (45–180)
0.02
sRANKL (pmol/L)
284 (101–1598)
292 (143–783)
0.8
OPG (pg/mL)
339 (52–1118)
527 (16–1030)
0.02
sRANKL/OPG
0.99 (0.14-22.6)
0.65 (0.14–25.1)
0.04
Sclerostin (pmol/L)
73 (48–126)
77 (49–110)
0.2
sFRP1 (ng/mL)
0.14 (0.1–16.7)
0.2 (0.1–1.2)
0.4
DKK1 (pg/mL) 97 (17–771) 115 (29–278) 0.7

Data are presented as the median with minimum and maximum values. ESR= erythrocyte sedimentation rate, hs-CRP= high sensitive C- reactive protein, IL-6= interleukin 6, IFNγ= interferon-gamma, BAP= bone-specific alkaline phosphatase, NTX= cross-linked N-telopeptide of type I collagen, TRAP 5= serum band 5 tartrate-resistant acid phosphatase, hPTH= human parathyroid hormone, sRANKL= soluble receptor activator of nuclear factor kappa-B ligand, OPG= osteoprotegerin, sFRP1= secreted frizzled-related protein 1, DKK1= Dickkopf-related protein 1.


[TableWrap ID: T2] Table 2 

Comparison of AS subjectswith respect to treatmenttype


  Anti-TNF treatment(n = 23) Conventional treatment(n = 32) pvalue
BASFI
3.7 (1.5–7.7)
3.8 (0.1–8.8)
0.4
BASDAI
4 (1.3–8.1)
5.5 (1–9)
0.08
BASRI-hip
0 (0–4)
0 (0–2.5)
0.1
BASRI-spine
7.5 (2–12)
5.5 (2–12)
0.09
BASMI
4 (1–9)
2 (1–9)
0.003
BMD-Lumbar spine (g/cm2)
1 (0.7–1.6)
0.9 (0.8–1.4)
0.3
BMD-Femoral neck (g/cm2)
0.8 (0.6–1)
0.8 (0.5–1.1)
0.5
IL-6 (pg/mL)
13 (5–545)
20 (6–300)
0.9
IFNγ (pg/ml)
0.002 (0.002–0.03)
0.002 (0.002–1.96)
0.6
BAP (U/L)
33 (17–107)
28 (13–47)
0.04
Vitamin D (nM)
84 (12–266)
92 (4–244)
0.9
NTX (nM, bone collagenequivalent)
78 (52–188)
83 (64–114)
0.4
TRAP 5 (U/L)
4 (2.3–5.8)
3.7 (2.3–6.6)
0.3
hPTH (pg/mL)
46 (44–130)
46 (44–170)
0.8
sRANKL (pmol/L)
284 (103–1598)
285 (101–956)
0.5
OPG (pg/mL)
274 (52–1080)
384 (84–1118)
0.04
sRANKL/OPG
1.28 (0.2–22.6)
0.73 (0.14–4.5)
0.03
Sclerostin (pmol/L)
75 (48–95)
68 (49–126)
0.6
sFRP1 (ng/mL)
0.1 (0.1–17)
0.2 (0.1–0.4)
0.1
DKK1 (pg/mL) 108 (39–771) 87 (17–370) 0.03

Data are presented as the median with minimum and maximum values. BASFI= Bath ankylosing apondylitis functional index, BASDAI= Bath ankylosing spondylitis disease activity index, BASMI= Bath ankylosing spondylitis metrology index, BASRI= Bath Ankylosing spondylitis radiologic index, IL-6= interleukin 6, IFNγ= interferon-gamma, BAP= bone-specific alkaline phosphatase, NTX= cross-linked N-telopeptide of type I collagen, TRAP 5= serum band 5 tartrate-resistant acid phosphatase, hPTH= human parathyroid hormone, sRANKL= soluble receptor activator of nuclear factor kappa-B ligand, OPG= osteoprotegerin, sFRP1= secreted frizzled-related protein 1, DKK1= Dickkopf-related protein 1.


[TableWrap ID: T3] Table 3 

Comparison of AS subjects with respect to disease activity


  Active patients(BASDAI ≥ 4; n= 38) Inactive patients(BASDAI < 4; n= 17) pvalue
IL-6 (pg/mL)
20 (6–545)
15 (5–277)
0.2
IFNγ (pg/mL)
0.002 (0.002–1.96)
0.002 (0.002–0.89)
0.7
BAP (U/L)
28 (13–107)
30 (15–49)
0.3
Vitamin D (nM)
89 (4–266)
77 (12–240)
0.6
NTX (nM, bone collagenequivalent)
87 (56–131)
81 (52–188)
0.7
TRAP 5 (U/L)
3.7 (2.2–5.8)
3.9 (2.4–6.6)
0.4
hPTH (pg/mL)
46 (44–170)
77 (45–130)
0.08
sRANKL (pmol/L)
264 (101–956)
350 (158–1598)
0.2
OPG (pg/mL)
367 (52–1118)
274 (71–592)
0.004
sRANKL/OPG
0.79 (0.14–4.5)
1.16 (0.4–22.6)
0.02
Sclerostin (pmol/L)
70 (49–126)
75 (48–123)
0.7
sFRP1 (ng/mL)
0.15 (0.1–17)
0.1 (0.1–0.2)
0.5
DKK1 (pg/mL)
93 (26–370)
130 (17–771)
0.5
BASRI-hip
0 (0–4)
0.5 (0–4)
0.2
BASRI-spine
5.5 (2–12)
7 (2–12)
0.3
BASMI
4 (1–9)
2.5 (1–9)
0.7
BMD-Lumbar spine (g/cm2)
0.9 (0.7–1.4)
0.9 (0.7–1.6)
0.8
BMD-Femoral neck (g/cm2) 0.7 (0.6–1.1) 0.8 (0.5–1) 0.9

Data are presented as the median with minimum and maximum values. BASDAI= Bath ankylosing spondylitis disease activity index, IL-6= interleukin 6, IFNγ= interferon-gamma, BAP= bone-specific alkaline phosphatase, NTX= cross-linked N-telopeptide of type I collagen, TRAP 5= serum band 5 tartrate-resistant acid phosphatase, hPTH= human parathyroid hormone, sRANKL= soluble receptor activator of nuclear factor kappa-B ligand, OPG= osteoprotegerin, sFRP1= secreted frizzled-related protein 1, DKK1= Dickkopf-related protein 1, BASRI= Bath Ankylosing spondylitis radiologic index, BASMI= Bath ankylosing spondylitis metrology index.


[TableWrap ID: T4] Table 4 

Correlation coefficients of the some clinical and laboratory data


  Disease duration BASRI-h BASRI-s BMD-f BMD-l BASDAI ≥4 BASMI hsCRP OPG sRANKL Sclerostin DKK1 sFRP1
Disease duration
 
0.3
0.6
 
0.3
 
0.6
 
 
−0.3
0.3
 
 
BASRI-h
0.3
 
0.6
 
 
−0.3
0.5
0.4
 
 
 
 
 
BASRI-s
0.6
0.6
 
 
0.3
 
0.7
0.3
 
−0.4
 
 
 
BMD-f
 
 
 
 
0.3
 
 
 
 
 
 
 
 
BMD-l
0.3
 
0.3
0.3
 
 
0.4
 
 
 
0.2
 
 
BASDAI ≥ 4
 
−0.3
 
 
 
 
 
 
0.3
 
 
 
 
BASMI
0.6
0.5
0.7
 
0.4
 
 
 
 
−0.4
 
0.3
 
hsCRP
 
0.4
0.3
 
 
 
 
 
 
 
 
 
 
OPG
 
 
 
 
 
0.3
 
 
 
 
 
 
 
sRANKL
−0.3
 
−0.4
 
 
 
−0.4
 
 
 
 
 
−0.2
Sclerostin
0.3
 
 
 
0.2
 
 
 
 
 
 
0.2
 
DKK1
 
 
 
 
 
 
0.3
 
 
 
0.2
 
−0.2
sFRP1                       −0.2  

Values indicate correlation coefficients. Note that empthy cells indicate no significance between variables. BASRI-h, and BASRI-s= Bath ankylosing spondylitis radiology index hip, and spine respectively, BMD-f, and BMD-l= BMD femoral neck and lumbar spine respectively, BASFI= Bath ankylosing apondylitis functional index, BASDAI= Bath ankylosing spondylitis disease activity index, BASMI= Bath ankylosing spondylitis metrology index, sRANKL= soluble receptor activator of nuclear factor kappa-B ligand, OPG= osteoprotegerin, sFRP1= secreted frizzled-related protein 1, DKK1= Dickkopf-related protein 1.



Article Categories:
  • Research Article

Keywords: Ankylosing spondylitis, Bone mineral density, OPG, RANKL, DKK-1.

Previous Document:  Xentrivalpeptides A-Q: Depsipeptide Diversification in Xenorhabdus.
Next Document:  Global DNA Methylation Not Increased in Chronic Hemodialysis Patients: A Case-Control Study.